Factor IX deficiency
RecruitingStudy on the Safety and Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Adults with Severe or Moderately Severe Hemophilia B and AAV5 Antibodies
Study on the Safety and Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Adults with Severe or Moderately Severe Hemophilia B and AAV5 Antibodies
- Disease:Factor IX deficiency
- Substances:Etranacogene Dezaparvovec
Bulgaria- Participants:18–64 years · 65+ years
- Substances:Etranacogene Dezaparvovec
- Sponsor:CSL Behring LLC
















